We report outcomes of a retrospective, single-institution experience with consolidative radiation after chemotherapy in metastatic urothelial cancer (MUC).
Patients and Methods
From our single-institution database of 2597 patients with urothelial carcinoma treated since 1997, we identified 22 patients with MUC who underwent consolidative radiotherapy after a partial response to chemotherapy with the intent of rendering them disease-free. All patients had undergone primary surgical therapy with either cystectomy or nephroureterectomy. Progression-free survival (PFS) was defined as time from completion of radiation therapy to relapse or last follow-up. Overall survival (OS) was defined as time from start of chemotherapy to death or last follow-up.
In the selected group of patients with MUC, the median age was 67 years; 59% had received previous cisplatin-based chemotherapy. The most common sites radiated were the regional lymph nodes (64%). Other radiated sites included the lung, adrenal glands, and omental metastases. Median survival from diagnosis to cystectomy was 48 months. Median PFS was 13 months and median OS was 29 months. Eight patients (36%) were alive and disease-free 6 years after radiation therapy. Patients who were rendered disease-free were those with nodal metastases and delivery of radiation to a single site of metastasis.
In this highly selective cohort of patients with MUC treated with consolidative radiation after chemotherapy, 36% were rendered disease-free. This suggests that radiation is feasible and might contribute to long-term disease control. Further prospective studies are needed to better characterize the benefit of combined modality treatment.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Clinical Genitourinary Cancer
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer.J Clin Oncol. 2005; 23: 4602-4608
- Pattern of failure and survival of patients with metastatic urothelial tumors relapsing after cis-platinum-based chemotherapy.J Urol. 1994; 151 ([discussion: 600-1]): 598-600
- Outcome of patients with grossly node positive bladder cancer after pelvic lymph node dissection and radical cystectomy.J Urol. 2001; 165: 62-64
- Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder?.J Urol. 2003; 169: 2113-2117
- Management of patients with advanced bladder cancer following major response to systemic chemotherapy.Expert Rev Anticancer Ther. 2009; 9: 1757-1764
- Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer.N Engl J Med. 2012; 366: 1477-1488
- Benchmarks achieved in the delivery of radiation therapy for muscle-invasive bladder cancer.Urol Oncol. 2007; 25: 76-84
- Post-chemotherapy surgery in patients with unresectable or regionally metastatic bladder cancer.J Urol. 2001; 165: 811-814
- Outcome of patients with clinically node-positive bladder cancer undergoing consolidative surgery after preoperative chemotherapy: the M.D. Anderson Cancer Center Experience.Urol Oncol. 2016; 34: 59.e1-59.e8
- Pelvic chemoradiotherapy after chemotherapy for metastatic bladder cancer.Can J Urol. 2006; 13: 3009-3015
- Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.N Engl J Med. 2003; 349: 859-866
Published online: April 13, 2017
Accepted: April 3, 2017
Received in revised form: March 24, 2017
Received: January 4, 2017
© 2017 Elsevier Inc. All rights reserved.